QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Correction An erratum has been published All Versions of this Article: jpet.103.060533v1 308/3/1073    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Xie, H. Articles by Blättler, W. A. Search for Related Content PubMed PubMed Citation Articles by Xie, H. Articles by Blättler, W. A. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB TRITIUM

ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION

Pharmacokinetics and Biodistribution of the Antitumor Immunoconjugate, Cantuzumab Mertansine (huC242-DM1), and Its Two Components in Mice

ImmunoGen, Inc., Cambridge, Massachusetts

The humanized monoclonal antibody maytansinoid conjugate, cantuzumab mertansine (huC242-DM1) that contains on average three to four linked drug molecules per antibody molecule was evaluated in CD-1 mice for its pharmacokinetic behavior and tissue distribution, and the results were compared with those of the free antibody huC242. The pharmacokinetics in blood were similar for ¹²⁵I-labeled conjugate and antibody with terminal half-lives of 154 and 156 h, respectively. Pharmacokinetic analysis using an enzyme-linked immunosorbent assay (ELISA) method, which measures intact conjugate in plasma samples revealed a faster clearance for the conjugate corresponding to a half-life of 42.2 h. This faster clearance is explained as the result of clearance from circulation and concomitant clearance of drug from circulating conjugate through linker cleavage. An antibody-specific ELISA allowed the determination of the clearance rate of the antibody component from circulation. The drug clearance rate from circulating conjugate was then calculated as the difference between the clearance of the conjugate and the clearance of the antibody component and found to be about three times that of the antibody component. The above results were confirmed with a conjugate, huC242-[³H]DM1, where the linked DM1 drugs carried a stable tritium label. Tissue distribution studies with ¹²⁵I-labeled conjugate and antibody showed antibody-like behavior for the conjugate; the antibody of the conjugate did not distribute or bind significantly to any solid tissue.

Address correspondence to: Hongsheng Xie, ImmunoGen, Inc., 128 Sidney Street, Cambridge, MA 02139. E-mail: hongsheng.xie{at}immunogen.com

This article has been cited by other articles:

				G. D. Lewis Phillips, G. Li, D. L. Dugger, L. M. Crocker, K. L. Parsons, E. Mai, W. A. Blattler, J. M. Lambert, R. V.J. Chari, R. J. Lutz, et al. Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate Cancer Res., November 15, 2008; 68(22): 9280 - 9290. [Abstract] [Full Text] [PDF]

				K. M. Kim, C. F. McDonagh, L. Westendorf, L. L. Brown, D. Sussman, T. Feist, R. Lyon, S. C. Alley, N. M. Okeley, X. Zhang, et al. Anti-CD30 diabody-drug conjugates with potent antitumor activity Mol. Cancer Ther., August 1, 2008; 7(8): 2486 - 2497. [Abstract] [Full Text] [PDF]

				E. Ostermann, P. Garin-Chesa, K. H. Heider, M. Kalat, H. Lamche, C. Puri, D. Kerjaschki, W. J. Rettig, and G. R. Adolf Effective Immunoconjugate Therapy in Cancer Models Targeting a Serine Protease of Tumor Fibroblasts Clin. Cancer Res., July 15, 2008; 14(14): 4584 - 4592. [Abstract] [Full Text] [PDF]

				J. A. Reddy, E. Westrick, H. K.R. Santhapuram, S. J. Howard, M. L. Miller, M. Vetzel, I. Vlahov, R. V.J. Chari, V. S. Goldmacher, and C. P. Leamon Folate Receptor-Specific Antitumor Activity of EC131, a Folate-Maytansinoid Conjugate Cancer Res., July 1, 2007; 67(13): 6376 - 6382. [Abstract] [Full Text] [PDF]

				H. K. Erickson, P. U. Park, W. C. Widdison, Y. V. Kovtun, L. M. Garrett, K. Hoffman, R. J. Lutz, V. S. Goldmacher, and W. A. Blattler Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res., April 15, 2006; 66(8): 4426 - 4433. [Abstract] [Full Text] [PDF]

				Y. V. Kovtun, C. A. Audette, Y. Ye, H. Xie, M. F. Ruberti, S. J. Phinney, B. A. Leece, T. Chittenden, W. A. Blattler, and V. S. Goldmacher Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res., March 15, 2006; 66(6): 3214 - 3221. [Abstract] [Full Text] [PDF]

				R. J. Sanderson, M. A. Hering, S. F. James, M. M.C. Sun, S. O. Doronina, A. W. Siadak, P. D. Senter, and A. F. Wahl In vivo Drug-Linker Stability of an Anti-CD30 Dipeptide-Linked Auristatin Immunoconjugate Clin. Cancer Res., January 15, 2005; 11(2): 843 - 852. [Abstract] [Full Text] [PDF]

				M. D. Henry, S. Wen, M. D. Silva, S. Chandra, M. Milton, and P. J. Worland A Prostate-Specific Membrane Antigen-Targeted Monoclonal Antibody-Chemotherapeutic Conjugate Designed for the Treatment of Prostate Cancer Cancer Res., November 1, 2004; 64(21): 7995 - 8001. [Abstract] [Full Text] [PDF]